HT
IOVA icon

Headlands Technologies’s Iovance Biotherapeutics IOVA Stock Holding History

Headlands Technologies’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$578K Sell
138,839
-14,233
-9% -$54.1K 0.06% 380
2026
Q1 		$537K Buy
153,072
+82,410
+117% +$264K 0.06% 344
2025
Q4 		$193K Buy
+70,662
New +$163K 0.02% 599
2025
Q1 		– Sell
-25,725
Closed -$190K – 1331
2024
Q4 		$190K Buy
+25,725
New +$238K 0.02% 535
2024
Q3 		– Sell
-16,067
Closed -$129K – 1358
2024
Q2 		$129K Buy
+16,067
New +$172K 0.01% 574

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Headlands Technologies's IOVA Position: Q2 2026 in Review

Headlands Technologies reduced its Iovance Biotherapeutics (IOVA) stake by 9.3% in Q2 2026, selling an estimated $54.1K and leaving 138,839 shares worth $578K. The position accounts for 0.06% of the portfolio, ranked #380.

Headlands Technologies first reported a position in IOVA in Q2 2024 and has held it in 5 quarters since. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Headlands Technologies held 138,839 shares of Iovance Biotherapeutics worth $578K as of Q2 2026.
  • Headlands Technologies sold 14,233 Iovance Biotherapeutics shares in Q2 2026, an estimated $54.1K.
  • Iovance Biotherapeutics made up 0.06% of Headlands Technologies's portfolio in Q2 2026, its #380 holding.
  • Headlands Technologies first reported a position in Iovance Biotherapeutics in Q2 2024 and has held it in 5 quarters since.
  • 293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.